---
document_datetime: 2025-12-02 05:12:30
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/imcivree.html
document_name: imcivree.html
version: success
processing_time: 0.1135128
conversion_datetime: 2025-12-29 21:10:46.665918
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Imcivree

[RSS](/en/individual-human-medicine.xml/67458)

##### Authorised

This medicine is authorised for use in the European Union

setmelanotide Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Imcivree](#news-on)
- [More information on Imcivree](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Imcivree is a medicine used to treat obesity and help control hunger caused by certain genetic conditions that affect how the brain controls feelings of hunger. It is used in adults and children aged 6 years and older with Bardet Biedl syndrome (BBS), and in those who have pro-opiomelanocortin (POMC) deficiency or leptin receptor (LEPR) deficiency resulting from changes (mutations) in both copies of the genes responsible for making POMC or LEPR.

Bardet Biedl syndrome, pro-opiomelanocortin deficiency and leptin receptor deficiency are rare, and Imcivree was designated an 'orphan medicine' (a medicine used in rare diseases). Further information on the orphan designations can be found on the European Medicines Agency's website ( [pro-opiomelanocortin deficiency](/en/medicines/human/orphan-designations/eu-3-16-1703) : 14 July 2016; [leptin receptor deficiency](/en/medicines/human/orphan-designations/eu-3-18-2101) : 19 November 2018; [Bardet Biedl syndrome](/en/medicines/human/orphan-designations/eu-3-19-2192) : 21 August 2019).

Imcivree contains the active substance setmelanotide.

Expand section

Collapse section

## How is Imcivree used?

Imcivree can only be obtained with a prescription and treatment should be prescribed and supervised by a doctor with expertise in treating obesity caused by genetic conditions.

Imcivree is given once a day as an injection under the skin. The dose depends on the condition being treated, the effect of the treatment and how well it is tolerated. After being trained, patients or carers can inject the medicine themselves.

For more information about using Imcivree, see the package leaflet or contact your healthcare provider.

## How does Imcivree work?

People with POMC deficiency have low levels of pro-opiomelanocortin, a substance that is converted into several hormones, including melanocyte-stimulating hormone (MSH). Low levels of MSH lead to loss of feeling of fullness after eating. In people with LEPR deficiency, the receptor (target) for the hormone leptin does not work properly so signals to the nerves that make the body feel full and control feelings of hunger cannot be sent. People with POMC, LEPR deficiency and BBS feel continuously hungry and quickly put on weight.

The active substance in Imcivree, setmelanotide, attaches to and activates a receptor called melanocortin receptor 4, which is normally activated through leptin and MSH, promoting a feeling of fullness after eating. By attaching to this receptor directly, Imcivree is expected to reduce excessive food intake and obesity.

## What benefits of Imcivree have been shown in studies?

In 2 main studies, Imcivree was shown to be effective at reducing body weight by at least 10% in people with POMC and LEPR deficiency.

The first study was carried out in 10 patients with obesity due to POMC deficiency resulting from mutations in both copies of the genes for either POMC or PCSK1. After one year of treatment, 8 out of 10 people achieved at least a 10% reduction in body weight.

In the second study carried out in 11 patients with obesity due to LEPR deficiency caused by mutations in both copies of the gene for LEPR, 5 people out of 11 achieved at least a 10% reduction in body weight after one year.

The studies also looked at the effects of Imcivree on the feeling of hunger as measured using a questionnaire: the percentage of patients who achieved at least a 25% reduction in hunger scores was 50% in the first study, and 73% in the second study.

In a study that included 28 patients aged 12 years or older with BBS, around 36% of the patients achieved at least a 10% reduction in body weight after one year of treatment.

Imcivree was not compared to another medicine in these studies.

## What are the risks associated with Imcivree?

The most common side effects with Imcivree (which may affect more than 1 in 10 people) are hyperpigmentation (coloration of the skin), injection site reaction, nausea (feeling sick), and headache.

For the full list of side effects and restrictions of Imcivree, see the package leaflet.

## Why is Imcivree authorised in the EU?

The number of people with BBS, POMC or LEPR deficiency is extremely small, so the number of people included in the studies was very limited. However, the studies showed that Imcivree helps to reduce bodyweight and feelings of hunger in these patients. These benefits are considered significant considering that there are no other medicines for these patients. Imcivree's side effects are manageable and long-term safety is monitored in a dedicated study after authorisation.

The European Medicines Agency therefore decided that Imcivree's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Imcivree?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Imcivree have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Imcivree are continuously monitored. Suspected side effects reported with Imcivree are carefully evaluated and any necessary action taken to protect patients.

## Other information about Imcivree

Imcivree received a marketing authorisation valid throughout the EU on 16 July 2021.

Imcivree : EPAR - Medicine overview

Reference Number: EMA/697512/2022

English (EN) (110.68 KB - PDF)

**First published:** 22/07/2021

**Last updated:** 07/02/2023

[View](/en/documents/overview/imcivree-epar-medicine-overview_en.pdf)

[Other languages (21)](#file-language-dropdown-716)

български (BG) (122.07 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/bg/documents/overview/imcivree-epar-medicine-overview_bg.pdf)

español (ES) (108.57 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/es/documents/overview/imcivree-epar-medicine-overview_es.pdf)

čeština (CS) (115.21 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/cs/documents/overview/imcivree-epar-medicine-overview_cs.pdf)

dansk (DA) (107.37 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/da/documents/overview/imcivree-epar-medicine-overview_da.pdf)

Deutsch (DE) (112.21 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/de/documents/overview/imcivree-epar-medicine-overview_de.pdf)

eesti keel (ET) (97.11 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/et/documents/overview/imcivree-epar-medicine-overview_et.pdf)

ελληνικά (EL) (121.52 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/el/documents/overview/imcivree-epar-medicine-overview_el.pdf)

français (FR) (112.77 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/fr/documents/overview/imcivree-epar-medicine-overview_fr.pdf)

hrvatski (HR) (110.96 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/hr/documents/overview/imcivree-epar-medicine-overview_hr.pdf)

latviešu valoda (LV) (121.63 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/lv/documents/overview/imcivree-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (114.26 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/lt/documents/overview/imcivree-epar-medicine-overview_lt.pdf)

magyar (HU) (112.41 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/hu/documents/overview/imcivree-epar-medicine-overview_hu.pdf)

Malti (MT) (115.35 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/mt/documents/overview/imcivree-epar-medicine-overview_mt.pdf)

Nederlands (NL) (109.43 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/nl/documents/overview/imcivree-epar-medicine-overview_nl.pdf)

polski (PL) (112.94 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/pl/documents/overview/imcivree-epar-medicine-overview_pl.pdf)

português (PT) (108.99 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/pt/documents/overview/imcivree-epar-medicine-overview_pt.pdf)

română (RO) (111.63 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/ro/documents/overview/imcivree-epar-medicine-overview_ro.pdf)

slovenčina (SK) (114.47 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/sk/documents/overview/imcivree-epar-medicine-overview_sk.pdf)

slovenščina (SL) (110.18 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/sl/documents/overview/imcivree-epar-medicine-overview_sl.pdf)

Suomi (FI) (107.64 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/fi/documents/overview/imcivree-epar-medicine-overview_fi.pdf)

svenska (SV) (105.77 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

07/02/2023

[View](/sv/documents/overview/imcivree-epar-medicine-overview_sv.pdf)

## Product information

Imcivree : EPAR - Product information

English (EN) (1.1 MB - PDF)

**First published:** 22/07/2021

**Last updated:** 03/06/2025

[View](/en/documents/product-information/imcivree-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-755)

български (BG) (1.65 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/bg/documents/product-information/imcivree-epar-product-information_bg.pdf)

español (ES) (1.42 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/es/documents/product-information/imcivree-epar-product-information_es.pdf)

čeština (CS) (1.67 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/cs/documents/product-information/imcivree-epar-product-information_cs.pdf)

dansk (DA) (1.3 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

27/10/2025

[View](/da/documents/product-information/imcivree-epar-product-information_da.pdf)

Deutsch (DE) (1.48 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/de/documents/product-information/imcivree-epar-product-information_de.pdf)

eesti keel (ET) (1.11 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/et/documents/product-information/imcivree-epar-product-information_et.pdf)

ελληνικά (EL) (1.62 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/el/documents/product-information/imcivree-epar-product-information_el.pdf)

français (FR) (1.57 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/fr/documents/product-information/imcivree-epar-product-information_fr.pdf)

hrvatski (HR) (1.65 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/hr/documents/product-information/imcivree-epar-product-information_hr.pdf)

íslenska (IS) (1.55 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/is/documents/product-information/imcivree-epar-product-information_is.pdf)

italiano (IT) (1.45 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/it/documents/product-information/imcivree-epar-product-information_it.pdf)

latviešu valoda (LV) (1.49 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/lv/documents/product-information/imcivree-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.44 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/lt/documents/product-information/imcivree-epar-product-information_lt.pdf)

magyar (HU) (1.61 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/hu/documents/product-information/imcivree-epar-product-information_hu.pdf)

Malti (MT) (1.76 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/mt/documents/product-information/imcivree-epar-product-information_mt.pdf)

Nederlands (NL) (1.42 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/nl/documents/product-information/imcivree-epar-product-information_nl.pdf)

norsk (NO) (1.56 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/no/documents/product-information/imcivree-epar-product-information_no.pdf)

polski (PL) (1.25 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/pl/documents/product-information/imcivree-epar-product-information_pl.pdf)

português (PT) (1.46 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/pt/documents/product-information/imcivree-epar-product-information_pt.pdf)

română (RO) (1.62 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/ro/documents/product-information/imcivree-epar-product-information_ro.pdf)

slovenčina (SK) (1.59 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/sk/documents/product-information/imcivree-epar-product-information_sk.pdf)

slovenščina (SL) (1.37 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

27/10/2025

[View](/sl/documents/product-information/imcivree-epar-product-information_sl.pdf)

Suomi (FI) (1.42 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/06/2025

[View](/fi/documents/product-information/imcivree-epar-product-information_fi.pdf)

svenska (SV) (1.3 MB - PDF)

**First published:**

22/07/2021

**Last updated:**

27/10/2025

[View](/sv/documents/product-information/imcivree-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0034 03/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Imcivree : EPAR - All authorised presentations

English (EN) (14.13 KB - PDF)

**First published:** 22/07/2021

**Last updated:** 03/11/2022

[View](/en/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-436)

български (BG) (42.03 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/bg/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_bg.pdf)

español (ES) (12.75 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/es/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_es.pdf)

čeština (CS) (31.71 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/cs/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (12.62 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/da/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (13.1 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/de/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (12.47 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/et/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (33.29 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/el/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_el.pdf)

français (FR) (12.24 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/fr/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (31.96 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/hr/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (12.97 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/is/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_is.pdf)

italiano (IT) (12.94 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/it/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (33.39 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/lv/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (21.74 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/lt/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (19.97 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/hu/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (31.75 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/mt/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (12.58 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/nl/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (12.6 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/no/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_no.pdf)

polski (PL) (41.43 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/pl/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_pl.pdf)

português (PT) (12.81 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/pt/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_pt.pdf)

română (RO) (31.85 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/ro/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (30.43 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/sk/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (25.52 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/sl/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (12.48 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/fi/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (12.65 KB - PDF)

**First published:**

22/07/2021

**Last updated:**

03/11/2022

[View](/sv/documents/all-authorised-presentations/imcivree-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Imcivree Active substance setmelanotide International non-proprietary name (INN) or common name setmelanotide Therapeutic area (MeSH) Obesity Anatomical therapeutic chemical (ATC) code A08AA

### Pharmacotherapeutic group

Antiobesity preparations, excl. diet products

### Therapeutic indication

IMCIVREE is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 2 years of age and above.

## Authorisation details

EMA product number EMEA/H/C/005089

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Rhythm Pharmaceuticals Netherlands B.V.

Radarweg 29

Opinion adopted 20/05/2021 Marketing authorisation issued 16/07/2021 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Imcivree : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (174.9 KB - PDF)

**First published:** 04/11/2021

**Last updated:** 03/06/2025

[View](/en/documents/procedural-steps-after/imcivree-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Imcivree-H-C-005089-P46-009 : EPAR - Assessment report

Adopted

Reference Number: EMA/438147/2024

English (EN) (707.53 KB - PDF)

**First published:** 18/09/2024

[View](/en/documents/variation-report/imcivree-h-c-005089-p46-009-epar-assessment-report_en.pdf)

CHMP post-authorisation summary of positive opinion for Imcivree (II-18)

Adopted

Reference Number: EMA/CHMP/277218/2024

English (EN) (92.67 KB - PDF)

**First published:** 28/06/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imcivree-ii-18_en.pdf)

Imcivree : EPAR - Orphan maintenance assessment report (post authorisation)

Adopted

Reference Number: EMA/OD/0000074865

English (EN) (285.06 KB - PDF)

**First published:** 28/09/2022

[View](/en/documents/orphan-maintenance-report-post/imcivree-epar-orphan-maintenance-assessment-report-post-authorisation_en.pdf)

Imcivree-H-C-005089-II-0002-G : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/677091/2022

English (EN) (5.1 MB - PDF)

**First published:** 28/09/2022

[View](/en/documents/variation-report/imcivree-h-c-005089-ii-0002-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Imcivree (II-02-G)

Adopted

Reference Number: EMA/639016/2022

English (EN) (100.01 KB - PDF)

**First published:** 22/07/2022

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imcivree-ii-02-g_en.pdf)

## Initial marketing authorisation documents

Imcivree : EPAR - Public assessment report

Adopted

Reference Number: EMA/402097/2024

English (EN) (2.05 MB - PDF)

**First published:** 30/09/2024

[View](/en/documents/assessment-report/imcivree-epar-public-assessment-report_en.pdf-0)

Imcivree : EPAR - Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMADOC-1700519818-687119

English (EN) (310.55 KB - PDF)

**First published:** 22/07/2021

[View](/en/documents/orphan-maintenance-report/imcivree-epar-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Imcivree : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/319064/2021

English (EN) (2.36 MB - PDF)

**First published:** 22/07/2021

[View](/en/documents/assessment-report/imcivree-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Imcivree

Adopted

Reference Number: EMA/CHMP/270677/2021

English (EN) (155.71 KB - PDF)

**First published:** 21/05/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-imcivree_en.pdf)

#### News on Imcivree

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024) 28/06/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022) 22/07/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022) 22/07/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021) 21/05/2021

[New treatment for obesity caused by rare genetic disorders](/en/news/new-treatment-obesity-caused-rare-genetic-disorders) 21/05/2021

#### More information on Imcivree

- [EU/3/16/1703 - orphan designation for treatment of pro-opiomelanocortin deficiency](/en/medicines/human/orphan-designations/eu-3-16-1703)
- [EMA/PE/0000182239 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/ema-pe-0000182239)
- [EU/3/18/2101 - orphan designation for treatment of leptin receptor deficiency](/en/medicines/human/orphan-designations/eu-3-18-2101)
- [EU/3/19/2192 - orphan designation for treatment of Bardet-Biedl syndrome](/en/medicines/human/orphan-designations/eu-3-19-2192)
- [Imcivree - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/imcivree)

**This page was last updated on** 03/06/2025

## Share this page

[Back to top](#main-content)